You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The dispute stems from a licensing agreement in 2005 covering reagent patents held by Abaxis. Cepheid filed a countersuit yesterday, claiming it has not breached the license and asking the court to declare Abaxis' patents invalid.
